Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia

Inclisiran, an investigational PCSK9-specific RNA silencing molecule with potential for a maintenance regimen of twice yearly dosing, significantly lowered LDL-C and PCSK9 in the dose-ranging ORION-1 trial. We report its efficacy and safety by diabetes status, and its impact on glycemia. ORION-1 ran...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2018-07, Vol.67 (Supplement_1)
Hauptverfasser: LEITER, LAWRENCE, TEOH, HWEE, KALLEND, DAVID, WRIGHT, R. SCOTT, LANDMESSER, ULF, WIJNGAARD, PETER L., KASTELEIN, JOHN J., RAY, KAUSIK K.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title Diabetes (New York, N.Y.)
container_volume 67
creator LEITER, LAWRENCE
TEOH, HWEE
KALLEND, DAVID
WRIGHT, R. SCOTT
LANDMESSER, ULF
WIJNGAARD, PETER L.
KASTELEIN, JOHN J.
RAY, KAUSIK K.
description Inclisiran, an investigational PCSK9-specific RNA silencing molecule with potential for a maintenance regimen of twice yearly dosing, significantly lowered LDL-C and PCSK9 in the dose-ranging ORION-1 trial. We report its efficacy and safety by diabetes status, and its impact on glycemia. ORION-1 randomized 501 persons with atherosclerosis (ASCVD) or ASCVD-risk equivalents, and high LDL-C despite maximally tolerated LDL-C lowering therapies, to inclisiran or placebo. Inclisiran significantly lowered LDL-C and PCSK9 similarly in persons with and without diabetes at day 180 (Table). Temporal A1C were similar in the placebo and incisiran arms (Figure). These data suggest that inclisiran is efficacious and does not worsen glycemia in persons with ASCVD or ASCVD-risk equivalents, regardless of their diabetes status, over 180 days.
doi_str_mv 10.2337/db18-337-OR
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_2337_db18_337_OR</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2337_db18_337_OR</sourcerecordid><originalsourceid>FETCH-LOGICAL-c78R-4619c7cec0da050687914092b38004e495e92afefddf1c643ab4cb0dd84802403</originalsourceid><addsrcrecordid>eNotkEFLwzAYhoMoWKcn_0DuEv3SZE1zlE7nsDDZBnoQSpp81cjWjqTb2L93RXkP73N6Dg8htxzuUyHUg6t5zk7A5oszknAtNBOp-jgnCQBPGVdaXZKrGH8AIDstIZ-z1q599MG0tOwOGCItJyUrqGkdfSuWr5rOQsC4Rdv7PdKuoRNvauwx0mVv-l2kB99_d7uevnchYuvbLzpdHy1uvLkmF41ZR7z5_xFZPT-tihdWzqez4rFkVuULJjOurbJowRkYQ5YrzSXotBY5gESpx6hT02DjXMNtJoWppa3BuVzmkEoQI3L3p7WhizFgU22D35hwrDhUQ5dq6FINMF-IX-ZlVgI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>LEITER, LAWRENCE ; TEOH, HWEE ; KALLEND, DAVID ; WRIGHT, R. SCOTT ; LANDMESSER, ULF ; WIJNGAARD, PETER L. ; KASTELEIN, JOHN J. ; RAY, KAUSIK K.</creator><creatorcontrib>LEITER, LAWRENCE ; TEOH, HWEE ; KALLEND, DAVID ; WRIGHT, R. SCOTT ; LANDMESSER, ULF ; WIJNGAARD, PETER L. ; KASTELEIN, JOHN J. ; RAY, KAUSIK K.</creatorcontrib><description>Inclisiran, an investigational PCSK9-specific RNA silencing molecule with potential for a maintenance regimen of twice yearly dosing, significantly lowered LDL-C and PCSK9 in the dose-ranging ORION-1 trial. We report its efficacy and safety by diabetes status, and its impact on glycemia. ORION-1 randomized 501 persons with atherosclerosis (ASCVD) or ASCVD-risk equivalents, and high LDL-C despite maximally tolerated LDL-C lowering therapies, to inclisiran or placebo. Inclisiran significantly lowered LDL-C and PCSK9 similarly in persons with and without diabetes at day 180 (Table). Temporal A1C were similar in the placebo and incisiran arms (Figure). These data suggest that inclisiran is efficacious and does not worsen glycemia in persons with ASCVD or ASCVD-risk equivalents, regardless of their diabetes status, over 180 days.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db18-337-OR</identifier><language>eng</language><ispartof>Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c78R-4619c7cec0da050687914092b38004e495e92afefddf1c643ab4cb0dd84802403</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>LEITER, LAWRENCE</creatorcontrib><creatorcontrib>TEOH, HWEE</creatorcontrib><creatorcontrib>KALLEND, DAVID</creatorcontrib><creatorcontrib>WRIGHT, R. SCOTT</creatorcontrib><creatorcontrib>LANDMESSER, ULF</creatorcontrib><creatorcontrib>WIJNGAARD, PETER L.</creatorcontrib><creatorcontrib>KASTELEIN, JOHN J.</creatorcontrib><creatorcontrib>RAY, KAUSIK K.</creatorcontrib><title>Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia</title><title>Diabetes (New York, N.Y.)</title><description>Inclisiran, an investigational PCSK9-specific RNA silencing molecule with potential for a maintenance regimen of twice yearly dosing, significantly lowered LDL-C and PCSK9 in the dose-ranging ORION-1 trial. We report its efficacy and safety by diabetes status, and its impact on glycemia. ORION-1 randomized 501 persons with atherosclerosis (ASCVD) or ASCVD-risk equivalents, and high LDL-C despite maximally tolerated LDL-C lowering therapies, to inclisiran or placebo. Inclisiran significantly lowered LDL-C and PCSK9 similarly in persons with and without diabetes at day 180 (Table). Temporal A1C were similar in the placebo and incisiran arms (Figure). These data suggest that inclisiran is efficacious and does not worsen glycemia in persons with ASCVD or ASCVD-risk equivalents, regardless of their diabetes status, over 180 days.</description><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNotkEFLwzAYhoMoWKcn_0DuEv3SZE1zlE7nsDDZBnoQSpp81cjWjqTb2L93RXkP73N6Dg8htxzuUyHUg6t5zk7A5oszknAtNBOp-jgnCQBPGVdaXZKrGH8AIDstIZ-z1q599MG0tOwOGCItJyUrqGkdfSuWr5rOQsC4Rdv7PdKuoRNvauwx0mVv-l2kB99_d7uevnchYuvbLzpdHy1uvLkmF41ZR7z5_xFZPT-tihdWzqez4rFkVuULJjOurbJowRkYQ5YrzSXotBY5gESpx6hT02DjXMNtJoWppa3BuVzmkEoQI3L3p7WhizFgU22D35hwrDhUQ5dq6FINMF-IX-ZlVgI</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>LEITER, LAWRENCE</creator><creator>TEOH, HWEE</creator><creator>KALLEND, DAVID</creator><creator>WRIGHT, R. SCOTT</creator><creator>LANDMESSER, ULF</creator><creator>WIJNGAARD, PETER L.</creator><creator>KASTELEIN, JOHN J.</creator><creator>RAY, KAUSIK K.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20180701</creationdate><title>Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia</title><author>LEITER, LAWRENCE ; TEOH, HWEE ; KALLEND, DAVID ; WRIGHT, R. SCOTT ; LANDMESSER, ULF ; WIJNGAARD, PETER L. ; KASTELEIN, JOHN J. ; RAY, KAUSIK K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c78R-4619c7cec0da050687914092b38004e495e92afefddf1c643ab4cb0dd84802403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LEITER, LAWRENCE</creatorcontrib><creatorcontrib>TEOH, HWEE</creatorcontrib><creatorcontrib>KALLEND, DAVID</creatorcontrib><creatorcontrib>WRIGHT, R. SCOTT</creatorcontrib><creatorcontrib>LANDMESSER, ULF</creatorcontrib><creatorcontrib>WIJNGAARD, PETER L.</creatorcontrib><creatorcontrib>KASTELEIN, JOHN J.</creatorcontrib><creatorcontrib>RAY, KAUSIK K.</creatorcontrib><collection>CrossRef</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LEITER, LAWRENCE</au><au>TEOH, HWEE</au><au>KALLEND, DAVID</au><au>WRIGHT, R. SCOTT</au><au>LANDMESSER, ULF</au><au>WIJNGAARD, PETER L.</au><au>KASTELEIN, JOHN J.</au><au>RAY, KAUSIK K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2018-07-01</date><risdate>2018</risdate><volume>67</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Inclisiran, an investigational PCSK9-specific RNA silencing molecule with potential for a maintenance regimen of twice yearly dosing, significantly lowered LDL-C and PCSK9 in the dose-ranging ORION-1 trial. We report its efficacy and safety by diabetes status, and its impact on glycemia. ORION-1 randomized 501 persons with atherosclerosis (ASCVD) or ASCVD-risk equivalents, and high LDL-C despite maximally tolerated LDL-C lowering therapies, to inclisiran or placebo. Inclisiran significantly lowered LDL-C and PCSK9 similarly in persons with and without diabetes at day 180 (Table). Temporal A1C were similar in the placebo and incisiran arms (Figure). These data suggest that inclisiran is efficacious and does not worsen glycemia in persons with ASCVD or ASCVD-risk equivalents, regardless of their diabetes status, over 180 days.</abstract><doi>10.2337/db18-337-OR</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)
issn 0012-1797
1939-327X
language eng
recordid cdi_crossref_primary_10_2337_db18_337_OR
source EZB-FREE-00999 freely available EZB journals; PubMed Central
title Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status without Worsening Glycemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A03%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inclisiran%20Lowers%20LDL-C%20and%20PCSK9%20Irrespective%20of%20Diabetes%20Status%20without%20Worsening%20Glycemia&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=LEITER,%20LAWRENCE&rft.date=2018-07-01&rft.volume=67&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db18-337-OR&rft_dat=%3Ccrossref%3E10_2337_db18_337_OR%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true